Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical-Biological Entity?
Daniela De Benedittis(Sapienza University of Rome), Roberto Latagliata(Ospedale di Belcolle), Annalina Piccioni(Azienda Ospedaliera San Giovanni Addolorata), Nicoletta Villivà(Azienda Sanitaria Locale Roma 3), Alessia Campagna(Humanitas University), Maria Antonietta Aloe Spiriti(Sapienza University of Rome), Ambra Di Veroli(University of Rome Tor Vergata), Luana Fianchi(Università Cattolica del Sacro Cuore), Ida Carmosino(Policlinico Umberto I), Pasquale Niscola(St. Eugenio Hospital), Stefano Mancini(Ospedale San Filippo Neri), Marco Mancini(Radboud University Nijmegen), Massimo Breccia(Policlinico Umberto I), Sara Mohamed(Royal College of Surgeons in Ireland - Bahrain), Francesco Buccisano(University of Rome Tor Vergata), Susanna Fenu(Azienda Ospedaliera San Giovanni Addolorata), Marianna Criscuolo(Università Cattolica del Sacro Cuore)
Cited by 2
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2018|1k
The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study.
|PubMed|2006|909